Management of Thrombocytopenia

Initial Assessment and Risk Stratification

The American College of Physicians recommends assessing bleeding risk factors beyond platelet count alone, including concurrent coagulopathy, liver/renal impairment, active infection, recent procedures, medication history, cancer treatment type, and history of prior bleeding episodes 1, 2

For patients with platelet counts ≥50,000/μL, the American Society of Hematology recommends no immediate intervention required in the absence of bleeding symptoms 1
For patients with platelet counts 25,000-50,000/μL, the American College of Cardiology recommends increased bleeding risk exists, but prophylactic platelet transfusion is NOT routinely indicated unless active significant bleeding occurs 2

The American Society of Hematology recommends treatment should be reserved for patients with clinically significant bleeding, not based solely on platelet count, with a goal to achieve platelet count ≥50,000/μL to reduce bleeding risk 1
For patients with platelet counts <30,000/μL with symptomatic bleeding, the International Society on Thrombosis and Haemostasis recommends corticosteroids (prednisone 1-2 mg/kg/day for maximum 14 days) with response in 1-7 days 1

The American College of Physicians recommends HIV and Hepatitis C testing, antiphospholipid antibody panel, antinuclear antibody (ANA), and serum immunoglobulins (IgG, IgA, IgM) for newly diagnosed ITP or unclear etiology 1, 4

The American Society of Hematology recommends platelet transfusion thresholds for procedures, including central venous catheter insertion (20,000/μL), lumbar puncture (40,000/μL), percutaneous tracheostomy or major surgery (50,000/μL), epidural catheter insertion/removal (80,000/μL), and neurosurgery (100,000/μL) 1

The American Heart Association recommends cessation of drugs reducing platelet function, control blood pressure, inhibition of menses, and avoidance of contact sports with high risk of head trauma 1, 4

The American Academy of Pediatrics recommends that majority of children with newly diagnosed ITP lack significant bleeding symptoms and may be managed without therapy ("watch and wait" policy) 4
The incidence of intracranial hemorrhage (ICH) in children is approximately 0.1-0.5% 4

The American Society of Hematology recommends not attempting to normalize platelet counts as a treatment goal, not using DOACs with platelets <50,000/μL, and not giving prophylactic platelet transfusions in ITP or TTP 1, 3

The American College of Physicians recommends weekly monitoring during dose adjustment phase of any treatment, monthly monitoring following establishment of stable dose, and daily monitoring when platelets <50,000/μL with active bleeding or requiring anticoagulation 1